CatalystAlertBeta

Loading market movers...

Arcutis Biotherapeutics, Inc.

ARQT

$3.46B

Mid Cap

NASDAQBiotechnology🇺🇸North America342 employees

Drugs in Pipeline

18

Phase 3 Programs

11

Upcoming Catalysts

2

Next Catalyst

Jun 15, 2026

13w

Market Overview

Stock performance and key metrics

ARQT News

Catalyst Timeline

2 upcoming, 0 past

No catalysts found.

2 more catalysts beyond 14 days

Start a 48h free trial to see all upcoming catalysts

Drug Pipeline

Roflumilast Cream 0.05%

Atopic Dermatitis

Roflumilast Foam 0.3%

Scalp Psoriasis

Topical roflumilast

Chronic Plaque Psoriasis

ARQ-151 0.3% cream

Chronic Plaque Psoriasis

Roflumilast Foam

Seborrheic Dermatitis

Roflumilast Cream

Atopic Dermatitis Eczema

Vehicle foam

Plaque Psoriasis

ARQ-151 Active

Atopic Dermatitis Eczema

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Atopic Dermatitis Eczema

Roflumilast Cream 0.15%

Atopic Dermatitis Eczema

Roflumilast 0.3% cream

Chronic Plaque Psoriasis

ARQ-151 cream 0.3%

Psoriasis

ARQ-252 cream 0.3%

Chronic Hand Eczema

ARQ-151 cream 0.5%

Psoriasis

ARQ-151 cream 0.05%

Atopic Dermatitis (Eczema)

Roflumilast Cream 0.3%

Plaque Psoriasis

Roflumilast

Plaque Psoriasis

ARQ-154

Seborrheic Dermatitis

Drug Name	Phase	Indication	Designations	Patent
Roflumilast Cream 0.05%	Phase 3	Atopic Dermatitis	-	-
Roflumilast Foam 0.3%	Phase 3	Scalp Psoriasis	-	-
Topical roflumilast	Phase 3	Chronic Plaque Psoriasis	-	-
ARQ-151 0.3% cream	Phase 3	Chronic Plaque Psoriasis	-	-
Roflumilast Foam	Phase 3	Seborrheic Dermatitis	-	-
Roflumilast Cream	Phase 3	Atopic Dermatitis Eczema	-	-
Vehicle foam	Phase 3	Plaque Psoriasis	-	-
ARQ-151 Active	Phase 3	Atopic Dermatitis Eczema	-	-
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Phase 3	Atopic Dermatitis Eczema	-	-
Roflumilast Cream 0.15%	Phase 3	Atopic Dermatitis Eczema	-	-
Roflumilast 0.3% cream	Phase 3	Chronic Plaque Psoriasis	-	-
ARQ-151 cream 0.3%	Phase 2	Psoriasis	-	-
ARQ-252 cream 0.3%	Phase 2	Chronic Hand Eczema	-	-
ARQ-151 cream 0.5%	Phase 2	Psoriasis	-	-
ARQ-151 cream 0.05%	Phase 2	Atopic Dermatitis (Eczema)	-	-
Roflumilast Cream 0.3%	Phase 2	Plaque Psoriasis	-	-
Roflumilast	Phase 2	Plaque Psoriasis	-	-
ARQ-154	Phase 2	Seborrheic Dermatitis	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply